Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
31 oct. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
26 oct. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
18 oct. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
11 oct. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
05 oct. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
04 oct. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
27 sept. 2023 08h01 HE
|
Mainz BioMed NV
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
20 sept. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
13 sept. 2023 03h01 HE
|
Mainz BioMed NV
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) --...
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
05 sept. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...